Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For All The Palace Intrigue, Rebate Rule, IPI Go To OMB For Review

Executive Summary

For all the rumors of political infighting, the two cornerstones of the Trump administration’s blueprint on drug pricing are in the final phase for review.

Advertisement

Related Content

Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
White House Exec Order Will Bring US Parity With Lowest Drug Prices Abroad, Trump Says
As Washington Waits On Pricing Proposals, A Call For A Reset In R&D Debate
Medicare Part B International Price Index Could Result In 25% R&D Cuts – Study
CMS Offers Part D Plans Financial Backstop If Rebates Eliminated In 2020

Topics

Advertisement
UsernamePublicRestriction

Register

PS125527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel